KR20200018383A - 천연 복합 호르몬 대체 제형 및 요법 - Google Patents
천연 복합 호르몬 대체 제형 및 요법 Download PDFInfo
- Publication number
- KR20200018383A KR20200018383A KR1020197019625A KR20197019625A KR20200018383A KR 20200018383 A KR20200018383 A KR 20200018383A KR 1020197019625 A KR1020197019625 A KR 1020197019625A KR 20197019625 A KR20197019625 A KR 20197019625A KR 20200018383 A KR20200018383 A KR 20200018383A
- Authority
- KR
- South Korea
- Prior art keywords
- estradiol
- progesterone
- subject
- max
- auc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430339P | 2016-12-05 | 2016-12-05 | |
| US62/430,339 | 2016-12-05 | ||
| US201762481060P | 2017-04-03 | 2017-04-03 | |
| US62/481,060 | 2017-04-03 | ||
| PCT/US2017/064788 WO2018136161A1 (en) | 2016-12-05 | 2017-12-05 | Natural combination hormone replacement formulations and therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200018383A true KR20200018383A (ko) | 2020-02-19 |
Family
ID=62908279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197019625A Ceased KR20200018383A (ko) | 2016-12-05 | 2018-02-02 | 천연 복합 호르몬 대체 제형 및 요법 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3548036A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020504093A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200018383A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110290793A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017394679A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019011655A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3045024A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267023A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019006513A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019115913A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018136161A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220105107A1 (en) * | 2020-10-01 | 2022-04-07 | Michael Liguori | Bioidentical progesterone cream infused with nanoemulsified cbd |
| GB202316026D0 (en) * | 2023-10-19 | 2023-12-06 | Theramex Hq Uk Ltd | Methods of prevention or treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| US6901278B1 (en) * | 2002-01-29 | 2005-05-31 | Morris Notelovitz | Methods for reducing the risk of breast cancer in and improving the health of women |
| US20040062794A1 (en) * | 2002-09-30 | 2004-04-01 | Lee Shulman | 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy |
| US9301920B2 (en) * | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| AR100562A1 (es) * | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
-
2017
- 2017-12-05 MX MX2019006513A patent/MX2019006513A/es unknown
- 2017-12-05 BR BR112019011655A patent/BR112019011655A2/pt not_active IP Right Cessation
- 2017-12-05 AU AU2017394679A patent/AU2017394679A1/en not_active Abandoned
- 2017-12-05 JP JP2019530027A patent/JP2020504093A/ja active Pending
- 2017-12-05 WO PCT/US2017/064788 patent/WO2018136161A1/en not_active Ceased
- 2017-12-05 CN CN201780086119.7A patent/CN110290793A/zh active Pending
- 2017-12-05 CA CA3045024A patent/CA3045024A1/en not_active Abandoned
- 2017-12-05 RU RU2019115913A patent/RU2019115913A/ru not_active Application Discontinuation
-
2018
- 2018-02-02 KR KR1020197019625A patent/KR20200018383A/ko not_active Ceased
- 2018-02-02 EP EP17893482.4A patent/EP3548036A4/en not_active Withdrawn
-
2019
- 2019-06-02 IL IL267023A patent/IL267023A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL267023A (en) | 2019-07-31 |
| RU2019115913A (ru) | 2021-01-15 |
| AU2017394679A1 (en) | 2019-06-13 |
| WO2018136161A1 (en) | 2018-07-26 |
| WO2018136161A9 (en) | 2019-08-22 |
| EP3548036A4 (en) | 2020-06-17 |
| RU2019115913A3 (cg-RX-API-DMAC7.html) | 2021-03-19 |
| MX2019006513A (es) | 2019-08-14 |
| JP2020504093A (ja) | 2020-02-06 |
| CN110290793A (zh) | 2019-09-27 |
| BR112019011655A2 (pt) | 2019-10-22 |
| EP3548036A1 (en) | 2019-10-09 |
| CA3045024A1 (en) | 2018-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180221389A1 (en) | Natural combination hormone replacement formulations and therapies | |
| Genazzani et al. | Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice | |
| Archer et al. | Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial | |
| Svigos et al. | A practical approach to the diagnosis and management of classic lichen planopilaris | |
| Sibai et al. | A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™) | |
| Modelska et al. | Tibolone for postmenopausal women: systematic review of randomized trials | |
| Shifren et al. | Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study | |
| Murphy et al. | Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding | |
| US20190247401A1 (en) | Natural combination hormone replacement formulations and therapies | |
| Casper et al. | A historical perspective of aromatase inhibitors for ovulation induction | |
| Simon et al. | Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms | |
| Mattsson et al. | Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms | |
| Skouby et al. | A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel | |
| Ettinger | Personal perspective on low-dosage estrogen therapy for postmenopausal women | |
| CA2644913A1 (en) | Methods for prevention and treatment of conditions arising from local estrogen deficiency | |
| KR20170005819A (ko) | 천연 복합 호르몬 대체 제형 및 요법 | |
| Sood et al. | Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial | |
| Archer | Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women | |
| Gast et al. | A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women | |
| JP2021525266A (ja) | 頸部障害の処置のためのロピナビルおよびリトナビル | |
| Ashraf et al. | The experience of a tertiary unit on the clinical phenotype and management of hypogonadism in female adolescents and young adults with transfusion dependent thalassemia | |
| Hedrick et al. | Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women | |
| Elkinson et al. | Ospemifene: first global approval | |
| Looby et al. | Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial | |
| JP2020504093A (ja) | 天然配合ホルモン補充製剤及び治療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190705 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210129 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221004 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230405 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20221004 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |